Epoetin Alfa Use in Patients With ESRD: An Analysis of Recent US Prescribing Patterns and Hemoglobin Outcomes
Authors:
- J. Michael LazarusJLJ. Michael Lazarus
- 1 September 2005
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 46 (3) , 481-488
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Hemoglobin variability in epoetin-treated hemodialysis patientsKidney International, 2003
- The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patientsKidney International, 2003
- Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokinesNephrology Dialysis Transplantation, 2002
- Vascular access use in Europe and the United States: Results from the DOPPSKidney International, 2002
- Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobinAmerican Journal of Kidney Diseases, 1999
- Follow-Up of Cardiac Changes Induced by Anemia Compensation in Normotensive Hemodialysis Patients with Left-Ventricular HypertrophyNephron, 1993
- rHuEPO treatment improves brain and cognitive function of anemic dialysis patientsKidney International, 1991
- Improved Physical Performance after Treatment of Renal Anemia with Recombinant Human ErythropoietinNephron, 1991
- Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietinThe Lancet, 1990
- The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial GroupJAMA, 1990